PhaseRx Announces Technology Evaluation Agreement with Monsanto

Monsanto to evaluate PhaseRx's SMARTT Polymer Technology® for potential agricultural applications.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Seattle, WA. (PRWEB) January 24, 2013

PhaseRx, Inc., a privately held RNAi delivery technology company, announced today that it has signed a funded technology evaluation agreement with Monsanto Company for PhaseRx's delivery technologies. Through the agreement, Monsanto will evaluate PhaseRx's SMARTT Polymer Technology® for potential agricultural applications. Terms of the agreement were not disclosed.

"This agreement with Monsanto represents PhaseRx's first project in the large and growing field of agriculture," said Robert Overell, Ph.D., President and Chief Executive Officer of PhaseRx, Inc. "It also helps further validate the breadth of PhaseRx platform capabilities beyond our primary focus applications."

About PhaseRx

PhaseRx is a privately held RNAi therapeutics company using its proprietary delivery technology to develop personalized medicines against key oncology targets. RNAi therapeutics represent a new class of pharmaceuticals with significant market potential, which has been hindered to date by the lack of effective delivery technology. PhaseRx's SMARTT Polymer Technology® offers effective intracellular RNAi delivery, broad candidate and therapeutic applicability, and robust and reproducible manufacturing. For more information about PhaseRx, please visit http://www.phaserx.com.

###


Contact

  • Kimberly Kraemer

    415-939-9033
    Email
  • Robert Overell, Ph.D. President and CEO
    PhaseRx
    206-805-6301